Condition
Drug Resistant
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Terminated2
Unknown1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07095933Early Phase 1Recruiting
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
NCT05198882Phase 1Unknown
Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy
NCT00376766Phase 3Terminated
Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)
NCT00228371Phase 2Terminated
STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy
Showing all 4 trials